FY2027 Earnings Estimate for INSP Issued By Leerink Partnrs

Inspire Medical Systems, Inc. (NYSE:INSP) – Research analysts at Leerink Partnrs dropped their FY2027 earnings estimates for Inspire Medical Systems in a research report issued on Tuesday, October 14th. Leerink Partnrs analyst M. Kratky now expects that the company will post earnings per share of $2.34 for the year, down from their previous estimate of $2.68. The consensus estimate for Inspire Medical Systems’ current full-year earnings is $2.16 per share. Leerink Partnrs also issued estimates for Inspire Medical Systems’ FY2028 earnings at $3.61 EPS.

Other equities research analysts also recently issued research reports about the stock. Evercore ISI decreased their price target on shares of Inspire Medical Systems from $150.00 to $125.00 and set an “outperform” rating on the stock in a research note on Tuesday, October 7th. Leerink Partners reduced their target price on shares of Inspire Medical Systems from $116.00 to $97.00 and set a “market perform” rating on the stock in a research note on Friday, August 15th. Morgan Stanley reduced their target price on shares of Inspire Medical Systems from $200.00 to $182.00 and set an “overweight” rating on the stock in a research note on Tuesday, July 15th. Truist Financial cut their price target on Inspire Medical Systems from $125.00 to $90.00 and set a “hold” rating for the company in a report on Wednesday. Finally, Piper Sandler cut their price target on Inspire Medical Systems from $233.00 to $150.00 and set an “overweight” rating for the company in a report on Tuesday, August 5th. Seven analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of $148.00.

Inspire Medical Systems Price Performance

INSP opened at $77.36 on Thursday. Inspire Medical Systems has a fifty-two week low of $70.77 and a fifty-two week high of $216.01. The firm’s fifty day moving average price is $82.87 and its two-hundred day moving average price is $119.54. The company has a market capitalization of $2.29 billion, a P/E ratio of 44.72, a P/E/G ratio of 2.46 and a beta of 1.16.

Inspire Medical Systems (NYSE:INSP) last announced its quarterly earnings data on Monday, August 4th. The company reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.22 by $0.23. The business had revenue of $217.09 million for the quarter, compared to the consensus estimate of $214.50 million. Inspire Medical Systems had a net margin of 6.17% and a return on equity of 10.38%. Inspire Medical Systems’s quarterly revenue was up 10.8% on a year-over-year basis. During the same quarter last year, the company posted $0.32 earnings per share. Inspire Medical Systems has set its FY 2025 guidance at 0.400-0.500 EPS.

Inspire Medical Systems announced that its board has initiated a share repurchase program on Monday, August 11th that allows the company to buyback $200.00 million in shares. This buyback authorization allows the company to repurchase up to 8.6% of its shares through open market purchases. Shares buyback programs are often an indication that the company’s board believes its shares are undervalued.

Insider Buying and Selling at Inspire Medical Systems

In related news, CFO Richard Buchholz sold 11,000 shares of the stock in a transaction that occurred on Friday, August 29th. The shares were sold at an average price of $93.39, for a total value of $1,027,290.00. Following the sale, the chief financial officer directly owned 44,867 shares in the company, valued at $4,190,129.13. This trade represents a 19.69% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 4.10% of the stock is owned by corporate insiders.

Institutional Trading of Inspire Medical Systems

A number of hedge funds have recently modified their holdings of INSP. GAMMA Investing LLC raised its position in shares of Inspire Medical Systems by 253.7% in the 1st quarter. GAMMA Investing LLC now owns 573 shares of the company’s stock valued at $91,000 after acquiring an additional 411 shares during the period. SG Americas Securities LLC increased its stake in Inspire Medical Systems by 14.7% during the 1st quarter. SG Americas Securities LLC now owns 4,055 shares of the company’s stock worth $646,000 after purchasing an additional 521 shares in the last quarter. Fifth Third Bancorp increased its stake in Inspire Medical Systems by 66.2% during the 1st quarter. Fifth Third Bancorp now owns 2,698 shares of the company’s stock worth $430,000 after purchasing an additional 1,075 shares in the last quarter. Exchange Traded Concepts LLC increased its stake in Inspire Medical Systems by 2,028.4% during the 1st quarter. Exchange Traded Concepts LLC now owns 10,706 shares of the company’s stock worth $1,705,000 after purchasing an additional 10,203 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. increased its stake in Inspire Medical Systems by 16.7% during the 1st quarter. Oppenheimer Asset Management Inc. now owns 15,206 shares of the company’s stock worth $2,422,000 after purchasing an additional 2,179 shares in the last quarter. 94.91% of the stock is currently owned by institutional investors and hedge funds.

About Inspire Medical Systems

Inspire Medical Systems, Inc, a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA.